Key Highlights

  • AngioDynamics' NanoKnife platform saw a 64.5% revenue spike in the fourth quarter of fiscal 2026, a significant acceleration for the company's key growth product.
  • The surge followed the implementation of Category I CPT codes, which provide clearer, more established billing pathways for physicians performing NanoKnife procedures.
  • A Palmetto GBA Medicare local coverage determination for prostate and liver indications further removed reimbursement uncertainty that had previously limited broader physician adoption.
  • These reimbursement milestones are a central driver behind the company's seventh consecutive period of double-digit Med Tech segment expansion.

AngioDynamics, Inc.'s (NASDAQ: ANGO) NanoKnife platform delivered a striking 64.5% revenue surge in the fourth quarter of fiscal 2026, marking a significant acceleration for what has become the company's central growth driver within its broader Med Tech segment. The scale of this quarterly acceleration highlights how significantly reimbursement policy changes can affect adoption curves for specialized medical device platforms.

NanoKnife is a irreversible electroporation-based tissue ablation platform, a technology that uses electrical pulses to destroy targeted tissue without relying on heat or cold-based ablation methods, offering a differentiated approach for treating tumors in anatomically sensitive locations where thermal ablation techniques may pose greater risk to surrounding structures.

The primary catalyst behind this quarter's dramatic acceleration was the implementation of Category I CPT codes for NanoKnife procedures. Category I CPT codes represent an important reimbursement milestone in the U.S. healthcare system, providing physicians and hospitals with established, well-defined billing codes for a given procedure, which in turn typically increases physician confidence in performing the procedure by reducing billing and reimbursement uncertainty that can otherwise limit adoption of newer medical technologies.

Compounding this reimbursement tailwind, AngioDynamics also secured a favorable Palmetto GBA Medicare local coverage determination specifically covering prostate and liver indications for NanoKnife. Local coverage determinations issued by Medicare Administrative Contractors like Palmetto GBA establish the specific conditions under which Medicare will provide coverage for a given procedure within their jurisdiction, and a favorable determination covering these two indications removes significant reimbursement risk for physicians treating Medicare-eligible patients with prostate or liver conditions using the NanoKnife platform.

Together, these two reimbursement developments — the Category I CPT code implementation and the Palmetto GBA coverage determination — appear to have unlocked a meaningfully faster adoption curve for NanoKnife, translating directly into the 64.5% quarterly revenue growth reported. For medical device companies, securing this kind of clear, favorable reimbursement pathway is often a more significant driver of near-term commercial acceleration than clinical data alone, since even a clinically effective technology can face slow adoption if physicians and hospitals face uncertainty about how procedures will be reimbursed.

This NanoKnife acceleration has been a central contributor to AngioDynamics' broader Med Tech segment achieving its seventh consecutive period of double-digit growth, and the durability of this reimbursement tailwind will likely remain a key factor investors watch as the company works toward its fiscal year 2027 guidance of $336.0 million to $341.0 million in net sales.